North Star Asset Management Inc. Purchases 1,722 Shares of Hologic, Inc. (NASDAQ:HOLX)

North Star Asset Management Inc. raised its position in Hologic, Inc. (NASDAQ:HOLX) by 0.7% in the 2nd quarter, Holdings Channel reports. The firm owned 249,594 shares of the medical equipment provider’s stock after buying an additional 1,722 shares during the period. North Star Asset Management Inc.’s holdings in Hologic were worth $18,532,000 at the end of the most recent quarter.

Several other hedge funds also recently bought and sold shares of the company. Norges Bank acquired a new stake in Hologic during the 4th quarter worth approximately $217,529,000. Price T Rowe Associates Inc. MD raised its holdings in shares of Hologic by 77.7% during the first quarter. Price T Rowe Associates Inc. MD now owns 6,297,197 shares of the medical equipment provider’s stock worth $490,931,000 after acquiring an additional 2,753,016 shares during the period. Swedbank AB bought a new stake in Hologic in the 1st quarter valued at $120,827,000. The Manufacturers Life Insurance Company increased its holdings in Hologic by 117.4% during the 4th quarter. The Manufacturers Life Insurance Company now owns 2,163,718 shares of the medical equipment provider’s stock worth $154,598,000 after purchasing an additional 1,168,564 shares in the last quarter. Finally, Cubist Systematic Strategies LLC raised its stake in shares of Hologic by 207.9% in the 4th quarter. Cubist Systematic Strategies LLC now owns 538,814 shares of the medical equipment provider’s stock valued at $38,498,000 after purchasing an additional 363,796 shares during the period. 94.73% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling at Hologic

In related news, insider Brandon Schnittker sold 476 shares of Hologic stock in a transaction that occurred on Tuesday, August 6th. The shares were sold at an average price of $83.11, for a total transaction of $39,560.36. Following the sale, the insider now directly owns 3,735 shares of the company’s stock, valued at approximately $310,415.85. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. In other Hologic news, insider Benjamin Jordan Cohn sold 5,093 shares of Hologic stock in a transaction dated Thursday, August 1st. The stock was sold at an average price of $81.99, for a total transaction of $417,575.07. Following the transaction, the insider now directly owns 10,476 shares of the company’s stock, valued at approximately $858,927.24. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, insider Brandon Schnittker sold 476 shares of the company’s stock in a transaction dated Tuesday, August 6th. The shares were sold at an average price of $83.11, for a total value of $39,560.36. Following the completion of the sale, the insider now owns 3,735 shares in the company, valued at approximately $310,415.85. The disclosure for this sale can be found here. Insiders have sold a total of 18,280 shares of company stock worth $1,469,973 over the last 90 days. Insiders own 1.75% of the company’s stock.

Wall Street Analysts Forecast Growth

Several brokerages have recently weighed in on HOLX. Royal Bank of Canada reaffirmed a “sector perform” rating and set a $82.00 price target on shares of Hologic in a research note on Friday, August 16th. Evercore ISI raised their target price on shares of Hologic from $76.00 to $78.00 and gave the company an “in-line” rating in a research report on Tuesday, July 30th. StockNews.com cut shares of Hologic from a “strong-buy” rating to a “buy” rating in a research report on Saturday, August 10th. Stephens restated an “overweight” rating and set a $92.00 price objective on shares of Hologic in a research note on Tuesday, July 30th. Finally, Needham & Company LLC reiterated a “buy” rating and set a $90.00 target price on shares of Hologic in a report on Tuesday, July 30th. Four investment analysts have rated the stock with a hold rating and eight have given a buy rating to the company. Based on data from MarketBeat.com, Hologic has a consensus rating of “Moderate Buy” and an average price target of $87.60.

Hologic Stock Performance

Shares of Hologic stock opened at $81.57 on Friday. The company has a 50 day moving average of $79.45 and a 200-day moving average of $76.63. The company has a market cap of $19.04 billion, a PE ratio of 41.62, a price-to-earnings-growth ratio of 2.57 and a beta of 0.99. The company has a current ratio of 3.99, a quick ratio of 3.32 and a debt-to-equity ratio of 0.51. Hologic, Inc. has a 1-year low of $64.02 and a 1-year high of $84.67.

Hologic (NASDAQ:HOLX) last issued its earnings results on Monday, July 29th. The medical equipment provider reported $1.06 earnings per share for the quarter, beating analysts’ consensus estimates of $1.02 by $0.04. Hologic had a return on equity of 19.53% and a net margin of 17.59%. The firm had revenue of $1.01 billion for the quarter, compared to the consensus estimate of $1 billion. During the same quarter last year, the business posted $0.93 EPS. The company’s revenue was up 2.7% compared to the same quarter last year. As a group, equities research analysts forecast that Hologic, Inc. will post 4.09 earnings per share for the current fiscal year.

Hologic Profile

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.